T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive form of leukemia that affects the T-cells, a type of white blood cell that plays a crucial role in the immune system. This condition is characterized by the proliferation of abnormal T-cells in the blood, bone marrow, and other tissues.

Pathophysiology

Prolymphocyte as seen under a microscope.

T-PLL is caused by genetic mutations that lead to the uncontrolled growth of T-cells. These mutations often involve the T-cell receptor genes and other regulatory genes that control cell growth and apoptosis. The abnormal T-cells in T-PLL are typically larger than normal T-cells and have a distinct appearance under the microscope, known as prolymphocytes.

Clinical Presentation

Patients with T-PLL often present with symptoms such as fatigue, night sweats, and weight loss. Physical examination may reveal lymphadenopathy, hepatosplenomegaly, and skin lesions. Laboratory findings typically show a high white blood cell count with a predominance of abnormal T-cells.

Diagnosis

The diagnosis of T-PLL is based on a combination of clinical findings, laboratory tests, and bone marrow biopsy. Flow cytometry is used to identify the specific immunophenotype of the T-cells, which is crucial for distinguishing T-PLL from other types of leukemia. Cytogenetic analysis may reveal characteristic chromosomal abnormalities.

Treatment

Treatment options for T-PLL are limited and often involve chemotherapy and immunotherapy. The monoclonal antibody alemtuzumab is commonly used in the treatment of T-PLL. In some cases, hematopoietic stem cell transplantation may be considered, especially in younger patients.

Prognosis

The prognosis for T-PLL is generally poor, with a median survival of less than two years. The aggressive nature of the disease and its resistance to conventional therapies contribute to the poor outcome.

Related pages

• Leukemia
• T lymphocyte
• Hematopoietic stem cell transplantation